

Phase I Clinical Study of WM-S1-030 in patients with advanced or metastatic solid tumor

Wellmarkerbio Co., Ltd.



ONCOLOGY	Phase 1
Product Type	Small Molecule
Indication	<ul style="list-style-type: none"> • 1st : Colorectal cancer • 2nd : NSCLCL, Cholangiocarcinoma, Head and Neck cancer, Pancreatic cancer
Target	Mutant CRG Kinase
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Mutant CRG is expressed on various cancers • WM-S1-030 is a mutant CRG kinase inhibitor • WM-S1-030 inhibits phosphorylation of mutant CRG • WM-S1-030 induces cell death and effectively suppresses tumor growth
Competitiveness	<ul style="list-style-type: none"> • WM-S1-030 is a novel small molecule inhibitor for the treatment of solid tumors • No competitive drugs for the same target, “First-in-Class” • Predictive biomarker
Development Stage	Phase I
Route of Administration	Oral Administration